Avidity Biosciences to Present New AOC 1001 Long-term Effica

John W. Day, MD, PhD, Professor of Neurology and Pediatrics, and Director, Division of Neuromuscular Medicine, Stanford University School of Medicine and a principal investigator in END-DM1,...

Related Keywords

Stanford University , California , United States , Orlando , Florida , San Diego , Navjot Rai , Geoffrey Grande , Stanford University School Of Medicine , Linkedin , Division Of Neuromuscular Medicine , Myotonic Dystrophy Clinical Research Network , Stanford University School Of Medicine On , Muscular Dystrophy Association , Avidity Biosciences Inc , Nasdaq , Neuromuscular Medicine , Stanford University School , Avidity Biosciences , Antibody Oligonucleotide Conjugates , Dystrophy Association , Scientific Conference , Novel Therapeutic Approach , Label Extension Study , Myotonic Dystrophy Type , Improving Muscle Function , Clinical Trial Participation , Clinical Trial Site , Oligonucleotide Conjugates , Annual Report , Private Securities Litigation Reform Act , Markets ,